Close Menu

NEW YORK – Accelerate Diagnostics and BioCheck announced on Tuesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a COVID-19 serology assay and test system.

The BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument will be marketed and commercialized by Accelerate Diagnostics following a commercial supply and collaboration agreement the firms forged in April.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.